Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 224

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer

Open access
Konstantinopoulos, Panagiotis A., Luo, Weixiu, Liu, Joyce F., Gulhan, Doga C., Krasner, Carolyn, Ishizuka, Jeffrey J., Gockley, Allison A., Buss, Mary, Growdon, Whitfield B., Crowe, Heather, Campos, Susana, Lindeman, Neal I., Hill, Sarah, Stover, Elizabeth, Schumer, Susan, Wright, Alexi A., Curtis, Jennifer, Quinn, Roxanne, Whalen, Christin, Gray, Kathryn P., Penson, Richard T., Cannistra, Stephen A., Fleming, Gini F., Matulonis, Ursula A. · 2019 · Journal of Clinical Oncology

Abstract

PURPOSE: Despite the tissue-agnostic approval of pembrolizumab in mismatch repair deficient (MMRD) solid tumors, important unanswered questions remain about the role of immune checkpoint blockade in mismatch repair–proficient (MMRP) and –deficient endometrial cancer (EC). METHODS: This phase II study evaluated the PD-L1 inhibitor avelumab in two cohorts of patients with EC: (1) MMRD/ POLE (polymerase ε) cohort, as defined by immunohistochemical (IHC) loss of expression of one or more mismatch repair (MMR) proteins and/or documented mutation in the exonuclease domain of POLE; and (2) MMRP cohort with normal IHC expression of all MMR proteins. Coprimary end points were objective response (OR) and progression-free survival at 6 months (PFS6). Avelumab 10 mg/kg intravenously was administered every 2 weeks until progression or unacceptable toxicity. RESULTS: Thirty-three patients were enrolled. No patient with POLE-mutated tumor was enrolled in the MMRD cohort, and all MMRP tumors were not POLE-mutated. The MMRP cohort was closed at the first stage because of futility: Only one of 16 patients exhibited both OR and PFS6 responses. The MMRD cohort met the predefined primary end point of four ORs after accrual of only 17 patients; of 15 patients who initiated avelumab, four exhibited OR (one complete response, three partial responses; OR rate, 26.7%; 95% CI, 7.8% to 55.1%) and six (including all four ORs) PFS6 responses (PFS6, 40.0%; 95% CI, 16.3% to 66.7%), four of which are ongoing as of data cutoff date. Responses were observed in the absence of PD-L1 expression. IHC captured all cases of MMRD subsequently determined by polymerase chain reaction or genomically via targeted sequencing. CONCLUSION: Avelumab exhibited promising activity in MMRD EC regardless of PD-L1 status. IHC for MMR assessment is a useful tool for patient selection. The activity of avelumab in MMRP/non- POLE–mutated ECs was low.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.19.01021

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 224

Metadata

Authors
Konstantinopoulos, P. A., Luo, W., Liu, J. F., Gulhan, D. C., Krasner, C., Ishizuka, J. J., Gockley, A. A., Buss, M., Growdon, W. B., Crowe, H., Campos, S., Lindeman, N. I., Hill, S., Stover, E., Schumer, S., Wright, A. A., Curtis, J., Quinn, R., Whalen, C., Gray, K. P., Penson, R. T., Cannistra, S. A., Fleming, G. F., & Matulonis, U. A.
Venue
Journal of Clinical Oncology
Published
2019-10-20
Volume
37
Issue
30
Pages
2786-2794
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2970410478
Cited by
224
References
6
FWCI
10.25
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. https://app.cochat.ai/papers/10.1200/jco.19.01021
The paper
Konstantinopoulos, P. A., Luo, W., Liu, J. F., Gulhan, D. C., Krasner, C., Ishizuka, J. J., Gockley, A. A., Buss, M., Growdon, W. B., Crowe, H., Campos, S., Lindeman, N. I., Hill, S., Stover, E., Schumer, S., Wright, A. A., Curtis, J., Quinn, R., Whalen, C., . . . Matulonis, U. A. (2019). Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.19.01021

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.